eli lilly glp 1 weight loss stock soars on encouraging results for daily weight-loss pill Eli Lilly First to Launch
Description
According to Evaluate, Lillys retatrutide (GLP-1/GIP/glucagon) hit 2324% in Phase 2, with 2030 sales modeled around $5.6B
CMAJ 192 , E875E891 (2020)
Guidance will need periodic revision as new evidence emerges
However, a clinical trial has shown that caffeine intake twice daily (200 mg) over 6 months did not produce significant symptomatic benefits for patients with PD [68]
